泰州迈博太科药业有限公司

外资(非欧美) 150-500人 制药/生物工程

公司简介

泰州迈博太科药业有限公司于2015年入驻泰州市中国医药城,注册资本2000万美元。公司主要从事单抗药物生产,投资总额2亿美元,拟建厂房面积3万余平方,建设符合GMP标准的国际先进的抗体药物制备体系,以期打造国内抗体药物生产高地。迈博太科药业由上海张江生物技术有限公司(抗体药物与靶向治疗国家重点实验室)抗体研发团队提供一站式平台服务,致力于实现一系列重量级国家创新抗体药物的产业化。现有品种:治疗结直肠癌的重组抗EGFR人鼠嵌合单克隆抗体,治疗银屑病的重组人LFA3-抗体融合蛋白等。 Taizhou Mabtech Pharmaceutical Co., Ltd. joined the China Medical City (CMC) in 2015 with registered capital of USD 20 million, expanding a national highland for monoclonal antibody medicine manufacturing by establishing internationally advanced antibody medicine manufacture system with adopted cGMP standards, with a total investment of USD 200 million. Supported by the one-stop platform for therapeutic mAb medicine development provided by ZJ-Bio R&D Team (State Key Laboratory of Antibody Medicine and Targeted Therapy), Taizhou Mabtech Pharmaceutics Co., Ltd is dedicated to industrialization of a series of “blockbuster” innovative antibody drugs. Existing varieties: recombinant anti-EGFR human/mouse-chimeric monoclonal antibody for the treatment of colorectal cancer, recombinant human LFA3-antibody fusion protein for the treatment of psoriasis , et al. 视 频 资 料 http://www.tz2100.com/news/dqxw/gx/2015/4/9/1428544031298.shtml

展开
收缩
公司地址:泰州医药高新技术产业园口泰路西侧、陆家路东侧 G79幢 (邮编:225312)
*发布本招聘广告企业的营业执照名称:泰州迈博太科药业有限公司
该公司所有职位
职位名称 地点 招聘人数 月薪范围 发布时间
猎才二维码